A double-blind, crossover, placebo-controlled, multiple-dose study to evaluate the effects of vildagliptin on gastric emptying, gastric volume and satiety in patients with type 2 diabetes.

Trial Profile

A double-blind, crossover, placebo-controlled, multiple-dose study to evaluate the effects of vildagliptin on gastric emptying, gastric volume and satiety in patients with type 2 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2012

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 04 May 2012 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov record (NCT00351507).
    • 04 May 2012 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov record (NCT00351507).
    • 07 Aug 2009 Planned end date (Feb 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top